Latest news with #Combiflam
Business Standard
03-05-2025
- Business
- Business Standard
Sanofi Consumer reports 20% YoY fall in Q1 PAT to Rs 50 cr
Sanofi Consumer Healthcare India (SCHIL) reported a 20.25% year-on-year (YoY) decline in net profit to Rs 50 crore for the quarter ended 31 March 2025, compared to Rs 62.70 crore in the same period last year. Revenue from operations fell 22.11% YoY to Rs 172.60 crore in the quarter ended 31 March 2025. On a sequential basis, net profit rose 12.86% and revenue increased 1.11% compared to Q4 2024. During the quarter, total expenses declined 12.10% YoY to Rs 111 crore, primarily due to a 71.70% reduction in the cost of materials consumed and a 29.34% decline in other expenses. Profit before tax slipped 20.38% to Rs 66.80 crore in the first quarter of 2025, compared to Rs 83.90 crore reported in the same period last year. The quarter also saw the successful launch of Allegra D, a new addition to the existing portfolio of Allegra variants in India a brand with over 25 years of legacy in the country. The company noted that Q1 2025 and Q1 2024 are not directly comparable due to the demerger and a voluntary product recall of certain key brand variants. Himanshu Bakshi, managing director, Sanofi Consumer Healthcare India, said, We continue to focus on strengthening our operations and continue to bring superior, simple and accessible products that enable consumers to control their own health. Our commitment to delivering high-quality, science-backed products remains at the core of our integrated growth strategy. SCHIL emerged as a distinct legal entity following its demerger from Sanofi India, executed under a Scheme of Arrangement approved by the Mumbai Bench of the National Company Law Tribunal, which became effective on 1 June 2024. This demerger aligns with Sanofi's global strategy, allowing SCHIL to operate independently with a focused mandate in the consumer healthcare sector. Sanofi Consumer Healthcare India is a leading player in India's consumer healthcare market. Leveraging Sanofis global experience, SCHIL aims to improve consumer well-being through a portfolio spanning allergy, digestive wellness, pain care, multivitamins, and herbal/traditional dietary supplements. Its key brands include Allegra, DePURA, Avil, and Combiflam. The scrip shed 0.08% to end at Rs 4,938.45 on the BSE on Friday.
&w=3840&q=100)
Business Standard
24-04-2025
- Business
- Business Standard
Investors rush to buy Sanofi India shares ahead of ex-dividend date; detail
Sanofi India Share Price, Dividend News: The shares of pharmaceutical company Sanofi India were in demand on the bourses on Thursday, April 24, 2024, ahead of their ex-dividend date. The company's share price advanced 4.39 per cent to ₹6,717.5 per share on the BSE during intra-day deals on Thursday. The company's shares continued to trade higher, and as of 1:27 PM on Thursday, they were quoted at ₹6,633.65 per share, up 3.09 per cent from the previous close. The upward movement in the company's share price aligns with the company's announcement of dividend rewards for its shareholders. Notably, the company's shares are set to trade ex-dividend tomorrow, April 25, 2024. The ex-dividend date marks the day a stock begins trading without the right to receive the declared dividend, meaning investors must own the stock before this date to be eligible. In an exchange filing, Sanofi India informed the bourses that its board has recommended a final dividend of ₹117 per equity share of the face value of ₹10 each for the financial year ended December 31, 2024. This, however, remains subject to the approval of shareholders at the ensuing 69th Annual General Meeting. Also Read: The pharmaceutical company has set Friday, April 25, 2025, as the record date to ascertain the shareholders' eligibility for the dividend payment. The company will finalize the list of eligible shareholders based on their records on the record date. Also Read At the current market price, Sanofi India's dividend yield stands at 1.77 per cent. Sanofi India dividend history: The pharmaceutical company has consistently rewarded its shareholders with dividend payouts. According to BSE data, Sanofi India paid an interim dividend of ₹50 per share and a final dividend of ₹117 per share in 2024. Earlier, in 2023, Sanofi India paid a special dividend of ₹183 per share and a final dividend of ₹194 per share to its shareholders. Historically, Sanofi India shares have exhibited mixed performance over the past year. The company's share price has advanced nearly 13 per cent in the last one month and 3 per cent in the last six months, while it has dropped nearly 19 per cent over the last year. Sanofi India shares have posted a gain of 9 per cent year-to-date, whereas the Sensex has advanced nearly 2 per cent this year. Sanofi India's shares have a 2-week range of ₹7,593.60 - ₹4,145.90 on the BSE. About Sanofi India: Sanofi India is primarily engaged in the business of manufacturing and trading of drugs and pharmaceuticals. It has its own manufacturing facilities in Goa and Ankleshwar, Gujarat. The pharmaceutical company sells products through independent distributors, primarily in India. Sanofi India's products, such as Lantus, Combiflam, Amaryl, and Allegra, feature in the top 100 pharmaceutical brands in India.
